Elisa Rubino

Dr. Elisa Rubino


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in The Lancet Neurology
Verified
Journal Article
Closed access
RFRaffaele Ferrari
Raffaele Ferrari
DHDena G Hernandez
Dena G Hernandez
MNMichael A Nalls
Michael A Nalls
JRJonathan D Rohrer
Jonathan D Rohrer
ARAdaikalavan Ramasamy
Adaikalavan Ramasamy
PMParastoo Momeni
Parastoo Momeni

9 October 2012 in Neurology
Verified
Journal Article
Closed access
PDF file
ERElisa Rubino
Elisa Rubino
IRInnocenzo Rainero
Innocenzo Rainero
ACAdriano Chiò
Adriano Chiò
EREkaterina Rogaeva
Ekaterina Rogaeva
DGDaniela Galimberti
Daniela Galimberti
CMCristina Moglia
Cristina Moglia
Objective: There is increasing evidence that common genetic risk factors underlie frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). Recently, mutations in the sequestosome 1 (SQSTM1) gene, which encodes p62 protein, have been reported in patients with ALS. P62 is a multifunctional adapter protein mainly involved in selective autophagy, oxidative stress response, and cell signaling pathways. The purpose of our study was to evaluate the frequency of SQSTM1 mutations in a dataset of unrelated patients with FTLD or ALS, in comparison with healthy controls and patients with Paget disease of bone (PDB). Methods: Promoter region and all exons of SQSTM1 were sequenced in a large group of subjects, including patients with FTLD or ALS, healthy controls, and patients with PDB. The clinical characteristics of patients with FTLD or ALS with gene mutations were examined. Results: We identified 6 missense mutations in the coding region of SQSTM1 in patients with either FTLD or ALS, none of which were found in healthy controls or patients with PDB. In silico analysis suggested a pathogenetic role for these mutations. Furthermore, 7 novel noncoding SQSTM1 variants were found in patients with FTLD and patients with ALS, including 4 variations in the promoter region. Conclusions: SQSTM1 mutations are present in patients with FTLD and patients with ALS. Additional studies are warranted in order to better investigate the role of p62 in the pathogenesis of both FTLD and ALS.

26 February 2015 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
ZXZhengrui Xi
Zhengrui Xi
MZMing Zhang
Ming Zhang
ABAmalia Cecilia Bruni
Amalia Cecilia Bruni
RMRaffaele G. Maletta
Raffaele G. Maletta
RCRosanna Colao
Rosanna Colao
EREkaterina Rogaeva
Ekaterina Rogaeva

1 September 2013 in Biological Psychiatry
Verified
Journal Article
Closed access
DGDaniela Galimberti
Daniela Galimberti
CFChiara Fenoglio
Chiara Fenoglio
MSMaria Serpente
Maria Serpente
Chiara VillaChiara Villa
Chiara Villa
RBRossana Bonsi
Rossana Bonsi
ESElio Scarpini
Elio Scarpini

12 October 2004 in Neurology
Verified
Journal Article
Closed access
PDF file
IRI. Rainero
I. Rainero
SGS. Gallone
S. Gallone
WVW. Valfrè
W. Valfrè
MFM. Ferrero
M. Ferrero
GAG. Angilella
G. Angilella
LPL. Pinessi
L. Pinessi
Several polymorphisms of the hypocretin/orexin system genes were evaluated in 109 cluster headache patients and 211 controls. The 1246 G>A polymorphism of the gene was significantly different between cases and controls. Homozygosity for the G allele was associated with an increased disease risk (OR: 6.79, 95% CI, 2.25 to 22.99). The data suggest that the HCRTR2 gene or a linked locus significantly modulates the risk for cluster headache.

1 August 2005 in Cephalalgia
Verified
Journal Article
Closed access
PDF file
IRI Rainero
I Rainero
PLP Limone
P Limone
MFM Ferrero
M Ferrero
WVW Valfrè
W Valfrè
CPC Pelissetto
C Pelissetto
LPL Pinessi
L Pinessi